Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aliskiren
Drug ID BADD_D00073
Description Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624]
Indications and Usage For the treatment of hypertension, to lower blood pressure.
Marketing Status Prescription
ATC Code C09XA02
DrugBank ID DB09026
KEGG ID D03208
MeSH ID C446481
PubChem ID 5493444
TTD Drug ID D03SVX
NDC Product Code 49884-425; 49884-424
Synonyms aliskiren | rasilez | Tekturna | CGP 060536B | CGP060536B | CGP-060536B | 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate | SPP100
Chemical Information
Molecular Formula C30H53N3O6
CAS Registry Number 173334-57-1
SMILES CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hepatomegaly09.01.05.0010.002793%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.004189%
Hyperkalaemia14.05.03.0010.019549%
Hypersensitivity10.01.03.0030.004189%
Hypertension24.08.02.0010.013964%
Hypoglycaemia14.06.03.001; 05.06.03.0010.006982%
Hypokalaemia14.05.03.0020.004189%
Hyponatraemia14.05.04.0020.002793%
Hypotension24.06.03.0020.011171%
Hypothyroidism05.02.03.001; 14.11.01.0120.002793%
Hypovolaemia14.05.05.0020.002793%Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.000729%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laryngeal pain22.02.05.036--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.005586%
Leukocytosis01.02.01.0020.002793%
Liver disorder09.01.08.001--Not Available
Loss of consciousness17.02.04.0040.005586%Not Available
Malaise08.01.01.0030.009775%
Metabolic acidosis14.01.01.0030.002793%Not Available
Mitral valve incompetence02.07.01.0020.002793%Not Available
Muscle spasms15.05.03.004--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages